Zymeworks Inc. (ZYME) stock

ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30141% above fair value

$26.47−2.60 (-8.94%)

Close on Nov 12, 2026Market cap $1.88BP/E 50.9Yield –

Zymeworks r&d expenses

Research and development expenses are spending on new products and technology.

Zymeworks's R&D Expenses for the twelve months ending Sep 30, 2026 was $129.25M, down 9.5% year over year. For fiscal 2025 it was $137.00M, up 1.8% from the year before. The highest annual figure on record is $208.60M in fiscal 2022.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$137.00M	+1.8%
FY2024	Dec 31, 2024	$134.62M	-6.3%
FY2023	Dec 31, 2023	$143.62M	-31.1%
FY2022	Dec 31, 2022	$208.60M	+4.4%
FY2021	Dec 31, 2021	$199.75M	+16.7%
FY2020	Dec 31, 2020	$171.20M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$36.13M	+1.5%
Q2 FY2026	Jun 30, 2026	$27.44M	-20.4%
Q1 FY2026	Mar 31, 2026	$34.46M	-3.6%
Q4 FY2025	Dec 31, 2025	$31.24M	-15.7%
Q3 FY2025	Sep 30, 2025	$35.58M	-2.1%
Q2 FY2025	Jun 30, 2025	$34.45M	+18.1%
Q1 FY2025	Mar 31, 2025	$35.74M	+11.5%
Q4 FY2024	Dec 31, 2024	$37.06M	+45.2%
Q3 FY2024	Sep 30, 2024	$36.35M	+10.9%
Q2 FY2024	Jun 30, 2024	$29.16M	-26.0%
Q1 FY2024	Mar 31, 2024	$32.04M	-30.2%
Q4 FY2023	Dec 31, 2023	$25.52M	-51.8%
Q3 FY2023	Sep 30, 2023	$32.78M	-11.7%
Q2 FY2023	Jun 30, 2023	$39.41M	-29.7%
Q1 FY2023	Mar 31, 2023	$45.91M	-26.6%
Q4 FY2022	Dec 31, 2022	$52.97M	-3.5%
Q3 FY2022	Sep 30, 2022	$37.10M	-25.6%
Q2 FY2022	Jun 30, 2022	$56.02M	–
Q1 FY2022	Mar 31, 2022	$62.51M	–
Q4 FY2021	Dec 31, 2021	$54.87M	–
Q3 FY2021	Sep 30, 2021	$49.89M	–